The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Medical Therapy for Secondary Prevention and Long-Term Outcome in Patients With Myocardial Infarction With Nonobstructive Coronary Artery Disease
Abstract
Background: Myocardial infarction with nonobstructive coronary arteries (MINOCA) occurs in 5% to 10% of all patients with myocardial infarction. Clinical trials of secondary prevention treatment in MINOCA patients are lacking. Therefore, the aim of this study was to examine the associations between treatment with statins, renin-angiotensin system blockers, β-blockers, dual antiplatelet therapy, and long-term cardiovascular events. Methods: This is an observational study of MINOCA patients recorded in the SWEDEHEART registry (the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapy) between July 2003 and June 2013 and followed until December 2013 for outcome events in the Swedish Cause of Death Register and National Patient Register. Of 199 162 myocardial infarction admissions, 9466 consecutive unique patients with MINOCA were identified. Among those, the 9136 patients surviving the first 30 days after discharge constituted the study population. Mean age was 65.3 years, and 61% were women. No patient was lost to follow-up. A stratified propensity score analysis was performed to match treated and untreated groups. The association between treatment and outcome was estimated by comparing between treated and untreated groups by using Cox proportional hazards models. The exposures were treatment at discharge with statins, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, β-blockers, and dual antiplatelet therapy. The primary end point was major adverse cardiac events defined as all-cause mortality, hospitalization for myocardial infarction, ischemic stroke, and heart failure. Results: At discharge, 84.5%, 64.1%, 83.4%, and 66.4% of the patients were on statins, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, β-blockers, and dual antiplatelet therapy, respectively. During the follow-up of a mean of 4.1 years, 2183 (23.9%) patients experienced a major adverse cardiac event. The hazard ratios (95% confidence intervals) for major adverse cardiac events were 0.77 (0.68–0.87), 0.82 (0.73–0.93), and 0.86 (0.74–1.01) in patients on statins, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and β-blockers, respectively. For patients on dual antiplatelet therapy followed for 1 year, the hazard ratio was 0.90 (0.74–1.08). Conclusions: The results indicate long-term beneficial effects of treatment with statins and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on outcome in patients with MINOCA, a trend toward a positive effect of β-blocker treatment, and a neutral effect of dual antiplatelet therapy. Properly powered randomized clinical trials to confirm these results are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Roffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy
Templin, C., Ghadri, J. R., Diekmann, J., Napp, L. C., Bataiosu, D. R., Jaguszewski, M., Cammann, V. L., Sarcon, A., Geyer, V., Neumann, C. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1406761 · Cited by 2,595
Pfeffer, M. A., McMurray, J. J. V., Velazquez, E. J., Rouleau, J.-L., Køber, L., Maggioni, A. P., Solomon, S. D., Swedberg, K., Van de Werf, F., White, H., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032292 · Cited by 2,471
Julian, D. G., Moss, A. J., Murray, G. D., Poole-Wilson, P. A., Simoons, M. L., Ball, S., Bender, N., Cleland, J. G. F., Dl, C., Pj, C., et al. (1993) · PubMed · Cited by 2,144
Julian, D. G., Moss, A. J., Murray, G. D., Poole-Wilson, P. A., Simoons, M. L., Ball, S., Bender, N., Cleland, J. G. F., Dl, C., Pj, C., et al. (1993) · The Lancet · Cited by 1,860
Interpretation of the evidence for the efficacy and safety of statin therapy
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31357-5 · Cited by 1,857
Angiographic progression of coronary artery disease and the development of myocardial infarction
Ambrose, J. A., Tannenbaum, M. A., Alexopoulos, D., Hjemdahl-Monsen, C. E., Leavy, J., Weiss, M., Borrico, S., Gorlin, R., & Fuster, V. (1988) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(88)90356-7 · Cited by 1,452
Cited by
Fourth universal definition of myocardial infarction (2018)
Thygesen, K., Alpert, J. S., Jaffe, A. S., Chaitman, B. R., Bax, J. J., Morrow, D. A., White, H. D., ESC Scientific Document Group, Thygesen, K., Alpert, J. S., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy462 · Cited by 5,880
Self-citationCollet, J.-P., Thiele, H., Barbato, E., Barthélémy, O., Bauersachs, J., Bhatt, D. L., Dendale, P., Dorobantu, M., Edvardsen, T., Folliguet, T., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa575 · Cited by 5,037
Fourth Universal Definition of Myocardial Infarction (2018)
Thygesen, K., Alpert, J. S., Jaffe, A. S., Chaitman, B. R., Bax, J. J., Morrow, D. A., & White, H. D. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.08.1038 · Cited by 4,118
Fourth Universal Definition of Myocardial Infarction (2018)
Thygesen, K., Alpert, J. S., Jaffe, A. S., Chaitman, B. R., Bax, J. J., Morrow, D. A., White, H. D., & The Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction (2018) · Circulation · doi:10.1161/cir.0000000000000617 · Cited by 3,799
Tamis-Holland, J. E., Jneid, H., Reynolds, H. R., Agewall, S., Brilakis, E. S., Brown, T. M., Lerman, A., Cushman, M., Kumbhani, D. J., Arslanian-Engoren, C., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000670 · Cited by 994
Bosco, E., Hsueh, L., McConeghy, K. W., Gravenstein, S., & Saade, E. (2021) · BMC Medical Research Methodology · doi:10.1186/s12874-021-01440-5 · Cited by 568
Fourth Universal Definition of Myocardial Infarction (2018)
Thygesen, K., Alpert, J. S., Jaffe, A. S., Chaitman, B. R., Bax, J. J., Morrow, D. A., & White, H. D. (2018) · Global Heart · doi:10.1016/j.gheart.2018.08.004 · Cited by 460
Safdar, B., Spatz, E. S., Dreyer, R. P., Beltrame, J. F., Lichtman, J. H., Spertus, J. A., Reynolds, H. R., Geda, M., Bueno, H., Dziura, J. D., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009174 · Cited by 451
DeFilippis, A. P., Chapman, A. R., Mills, N. L., de Lemos, J. A., Arbab-Zadeh, A., Newby, L. K., & Morrow, D. A. (2019) · Circulation · doi:10.1161/circulationaha.119.040631 · Cited by 387
Smilowitz, N. R., Mahajan, A. M., Roe, M. T., Hellkamp, A. S., Chiswell, K., Gulati, M., & Reynolds, H. R. (2017) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.116.003443 · Cited by 351
Kaski, J.-C., Crea, F., Gersh, B. J., & Camici, P. G. (2018) · Circulation · doi:10.1161/circulationaha.118.031373 · Cited by 340
Reynolds, H. R., Maehara, A., Kwong, R. Y., Sedlak, T., Saw, J., Smilowitz, N. R., Mahmud, E., Wei, J., Marzo, K., Matsumura, M., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.052008 · Cited by 323
Coronary Microvascular Dysfunction
Vancheri, F., Longo, G., Vancheri, S., & Henein, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092880 · Cited by 321
Padro, T., Manfrini, O., Bugiardini, R., Canty, J., Cenko, E., De Luca, G., Duncker, D. J., Eringa, E. C., Koller, A., Tousoulis, D., et al. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa003 · Cited by 294
Kontos, M. C., de Lemos, J. A., Deitelzweig, S. B., Diercks, D. B., Gore, M. O., Hess, E. P., McCarthy, C. P., McCord, J. K., Musey, P. I., Villines, T. C., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.08.750 · Cited by 260
Metadata
- Authors
- Lindahl, B., Baron, T., Erlinge, D., Hadziosmanovic, N., Nordenskjöld, A., Gard, A., & Jernberg, T.
- Venue
- Circulation
- Published
- 2017-04-18
- Volume
- 135
- Issue
- 16
- Pages
- 1481-1489
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2586296716
- Cited by
- 482
- References
- 28
- FWCI
- 27.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.